Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Antithymocyte Globulin (ATG)
DRUG: Teplizumab

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)